Tomoya Mizuno
Dokkyo Medical University
26 Papers
153 Citations
Tomoya Mizuno is an academic researcher from Dokkyo Medical University. The author has contributed to research in topics: Silodosin & Clear cell renal cell carcinoma. The author has an hindex of 11, co-authored 26 publications. Previous affiliations of Tomoya Mizuno include Dokkyo University.
Chat about Author
Papers
Randomized, Placebo Controlled Study of Electrical Stimulation With Pelvic Floor Muscle Training for Severe Urinary Incontinence After Radical Prostatectomy
TL;DR: Electrical stimulation resulted in earlier recovery of continence in patients with urinary incontinence after radical prostatectomy and the amount of leakage was significantly larger in the active group at 1 month but there was no difference at 12 months.
78
Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma
Hironori Betsunoh,Takehiko Fukuda,Naohiko Anzai,Daisaku Nishihara,Tomoya Mizuno,Hideo Yuki,Akinori Masuda,Yoshiyuki Yamaguchi,Hideyuki Abe,Masahiro Yashi,Yoshitatsu Fukabori,Ken-Ichiro Yoshida,Takao Kamai +12 more
TL;DR: Findings suggest that LAT1 mRNA is related to the invasive and progressive potential of clear cell RCC.
Urodynamic effects of silodosin, a new alpha1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia
Tomonori Yamanishi,Tomoya Mizuno,Ken-Ichiro Yoshida,Ryuji Sakakibara,Shinji Hirakawa +4 more
- 20 Aug 2007
TL;DR: In this article, the effects of silodosin, a new α1A•adrenoceptor•selective antagonist, in the treatment of benign prostatic hyperplasia (BPH) were investigated urodynamically.
46
Clinical Significance of Serum Soluble T Cell Regulatory Molecules in Clear Cell Renal Cell Carcinoma
Akinori Masuda,Kyoko Arai,Daisaku Nishihara,Tomoya Mizuno,Hideo Yuki,Tsunehito Kambara,Hironori Betsunoh,Hideyuki Abe,Masahiro Yashi,Yoshitatsu Fukabori,Ken-Ichiro Yoshida,Takao Kamai +11 more
TL;DR: The results indicate that the serum level of sIL-2R reflects tumor progression in CCRCC patients, and the possibility was suggested that the IL-2/IL- 2R and B7-H3 pathways may be involved in the progression of C CRCC.
Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma.
Nobutaka Furuya,Takao Kamai,Hiromichi Shirataki,Yoshiaki Yanai,Takehiko Fukuda,Tomoya Mizuno,Fumihiko Nakamura,Tsunehito Kambara,Kimihiro Nakanishi,Hideyuki Abe,Ken-Ichiro Yoshida +10 more
TL;DR: A high serum level of IFNAR2 mRNA may be a useful marker for predicting the response of metastatic RCC to IFN-alpha ± sorafenib therapy.
19